sclcWD22563_S71.txt
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.630
- INTERFERON_GAMMA_RESPONSE+0.590
- IL6_JAK_STAT3_SIGNALING+0.550
- INFLAMMATORY_RESPONSE+0.550
- INTERFERON_ALPHA_RESPONSE+0.530
- COAGULATION+0.500
- ALLOGRAFT_REJECTION+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- COMPLEMENT+0.440
- MYOGENESIS+0.430
Top 10 suppressed
- E2F_TARGETS-0.590
- MYC_TARGETS_V1-0.580
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V2-0.560
- DNA_REPAIR-0.480
- G2M_CHECKPOINT-0.480
- PROTEIN_SECRETION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.390
- WNT_BETA_CATENIN_SIGNALING-0.350
- MITOTIC_SPINDLE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3H71BH6Q | Ganglioglioma | — | 0.957 |
| 2 | BS_W97QQYKQ | Ganglioglioma | — | 0.948 |
| 3 | sclcA055A_S52.txt | — | cohortMD2 | 0.944 |
| 4 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.942 |
| 5 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.942 |
| 6 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.939 |
| 7 | ERR2598337 | fetal | fetal | 0.937 |
| 8 | sclc0617_S65.txt | — | cohortMD2 | 0.935 |
| 9 | MDT-AP-2892 | Med | Medulloblastoma | 0.934 |
| 10 | BS_S9929Z8B | Ganglioglioma | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |